Pancreatic cancer and FOLFIRINOX: a new era and new questions

Publisher： John Wiley & Sons Inc

E-ISSN： 2045-7634|4|6|853-863

ISSN： 2045-7634

Source： Cancer Medicine, Vol.4, Iss.6, 2015-06, pp. : 853-863

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Genetic Engineering - A New Era for Cancer Immunotherapy?

By  

Current Cancer Therapy Reviews, Vol. 3, Iss. 3, 2007-08 ,pp. : 194-198

Bentham Science Publishers

Access to resources Recommend Favorite

New Techniques and Agents in the Adjuvant Therapy of Pancreatic Cancer

By Raraty Michael G. T.   Magee Conor J.   Ghaneh Paula   Neoptolemos John P.  

Acta Oncologica, Vol. 41, Iss. 7-8, 2002-11 ,pp. : 582-595

Informa Healthcare

Access to resources Recommend Favorite

Old and new drugs in systemic therapy of pancreatic cancer

By Pasetto L.M.   Jirillo A.   Stefani M.   Monfardini S.  

Critical Reviews in Oncology/Hematology, Vol. 49, Iss. 2, 2004-02 ,pp. : 135-151

Elsevier

Access to resources Recommend Favorite

Defining New Paradigms for the Treatment of Pancreatic Cancer

By Almhanna Khaldoun  

Current Treatment Options in Oncology, Vol. 12, Iss. 2, 2011-06 ,pp. : 111-125

Springer Publishing Company

Access to resources Recommend Favorite

Female gender may predict response to FOLFIRINOX in patients with unresectable pancreatic cancer: A single institution retrospective review

By                  

International Journal of Oncology, Vol. 44, Iss. 1, 2014-01 ,pp. : 319-326

Spandidos Publications

Access to resources Recommend Favorite